Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.

@article{Hazell2011CoreAS,
  title={Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.},
  author={Philip Hazell and Michael R. Kohn and Ruth Dickson and Richard James Walton and Renee E. Granger and Gregory W van Wyk},
  journal={Journal of attention disorders},
  year={2011},
  volume={15 8},
  pages={674-83}
}
OBJECTIVE Previous studies comparing atomoxetine and methylphenidate to treat ADHD symptoms have been equivocal. This noninferiority meta-analysis compared core ADHD symptom response between atomoxetine and methylphenidate in children and adolescents. METHOD Selection criteria included randomized, controlled design; duration 6 weeks; and assessment of ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS) scores. Six-week response rates, defined as ≥40% reduction… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
( n = 557 ) , with atomoxetine demonstrating noninferiority to methylphenidate ( absolute difference -0.9% , 95% CI -9.2%-7.5% ) . CONCLUSION .
Core ADHD symptom improvement with atomoxetine versus methylphenidate : a direct comparison meta - analysis . OBJECTIVE .
After 6 weeks , 53.6% ( 95% confidence interval [ CI ] 48.6%-58.4% ) of atomoxetine - treated patients ( n = 811 ) had responded compared with 54.4% ( 47.6%-61.1% ) for methylphenidate
After 6 weeks of treatment atomoxetine and methylphenidate had comparable efficacy in reducing core ADHD symptoms in children and adolescents .
Previous studies comparing atomoxetine and methylphenidate to treat ADHD symptoms have been equivocal .
This noninferiority meta - analysis compared core ADHD symptom response between atomoxetine and methylphenidate in children and adolescents .
Core ADHD symptom improvement with atomoxetine versus methylphenidate : a direct comparison meta - analysis . OBJECTIVE .
Previous studies comparing atomoxetine and methylphenidate to treat ADHD symptoms have been equivocal .
This noninferiority meta - analysis compared core ADHD symptom response between atomoxetine and methylphenidate in children and adolescents .
After 6 weeks of treatment atomoxetine and methylphenidate had comparable efficacy in reducing core ADHD symptoms in children and adolescents .
After 6 weeks , 53.6% ( 95% confidence interval [ CI ] 48.6%-58.4% ) of atomoxetine - treated patients ( n = 811 ) had responded compared with 54.4% ( 47.6%-61.1% ) for methylphenidate
( n = 557 ) , with atomoxetine demonstrating noninferiority to methylphenidate ( absolute difference -0.9% , 95% CI -9.2%-7.5% ) . CONCLUSION .
After 6 weeks of treatment atomoxetine and methylphenidate had comparable efficacy in reducing core ADHD symptoms in children and adolescents .
This noninferiority meta - analysis compared core ADHD symptom response between atomoxetine and methylphenidate in children and adolescents .
Core ADHD symptom improvement with atomoxetine versus methylphenidate : a direct comparison meta - analysis . OBJECTIVE .
Previous studies comparing atomoxetine and methylphenidate to treat ADHD symptoms have been equivocal .
After 6 weeks of treatment atomoxetine and methylphenidate had comparable efficacy in reducing core ADHD symptoms in children and adolescents .
This noninferiority meta - analysis compared core ADHD symptom response between atomoxetine and methylphenidate in children and adolescents .
Core ADHD symptom improvement with atomoxetine versus methylphenidate : a direct comparison meta - analysis . OBJECTIVE .
Previous studies comparing atomoxetine and methylphenidate to treat ADHD symptoms have been equivocal .
All Topics